Literature DB >> 19295446

Investigation of autonomic function and orocecal transit time in patients with nonalcoholic cirrhosis and the potential influence of these factors on disease outcome.

Cristiane Kibune Nagasako1, Márcio Jansen de Oliveira Figueiredo, Jazon Romilson de Souza Almeida, Sônia Letícia Silva Lorena, Helena Midori Akasaka, Célia Regina Pavan, Ademar Yamanaka, Tiago Sevá Pereira, Elza Cotrim Soares, Maria Aparecida Mesquita.   

Abstract

BACKGROUND: The presence of autonomic dysfunction in nonalcoholic cirrhosis and its influence on intestinal transit and disease outcome still need clarification. GOALS: To investigate the function of the autonomic nervous system in patients with nonalcoholic cirrhosis and the possible associations among autonomic dysfunction, severity of liver disease, disturbed intestinal transit, and the development of complications during follow-up. STUDY: Measurements of heart rate variability obtained by analysis of 24-hour ambulatory electrocardiographic recordings to assess autonomic function and lactulose breath hydrogen test to determine orocecal transit time were performed in 32 patients with nonalcoholic cirrhosis divided into Child A and B.
RESULTS: Child B patients showed significantly lower values (P<0.05) of those parameters reflecting parasympathetic (high frequency, log-transformed high frequency, pNN50) and sympathetic function (low frequency, log-transformed low frequency) in comparison with controls and Child A patients. Orocecal transit time values were significantly (P=0.02) higher in Child B patients than in controls, but no relationship was found between delayed orocecal transit time and autonomic dysfunction. During follow-up, 42% of Child B patients developed encephalopathy. This complication was significantly associated with autonomic dysfunction. In addition, in the 4 patients who died the parameters reflecting parasympathetic function were significantly reduced in comparison with those of survivors.
CONCLUSIONS: Autonomic dysfunction and delayed intestinal transit are related to the severity of disease in nonalcoholic cirrhosis. Autonomic dysfunction seems to predispose cirrhotic patients to the development of encephalopathy and may be associated with a poor prognosis of these patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19295446     DOI: 10.1097/MCG.0b013e31818de34c

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  7 in total

Review 1.  What does irritable bowel syndrome share with non-alcoholic fatty liver disease?

Authors:  Antonella Scalera; Matteo Nicola Dario Di Minno; Giovanni Tarantino
Journal:  World J Gastroenterol       Date:  2013-09-07       Impact factor: 5.742

Review 2.  Small Intestinal Bacterial Overgrowth in Patients With Cirrhosis.

Authors:  Gaurav Ghosh; Arun B Jesudian
Journal:  J Clin Exp Hepatol       Date:  2018-08-27

Review 3.  Gastrointestinal dysfunction in liver cirrhosis.

Authors:  Evangelos Kalaitzakis
Journal:  World J Gastroenterol       Date:  2014-10-28       Impact factor: 5.742

4.  Small intestinal bacterial overgrowth and delayed orocecal transit time in patients with cirrhosis and low-grade hepatic encephalopathy.

Authors:  Manish Kumar Lunia; Barjesh Chander Sharma; Sanjeev Sachdeva
Journal:  Hepatol Int       Date:  2012-03-15       Impact factor: 6.047

Review 5.  Changes of Intestinal Functions in Liver Cirrhosis.

Authors:  Hiroshi Fukui; Reiner Wiest
Journal:  Inflamm Intest Dis       Date:  2016-03-08

Review 6.  Gastrointestinal Motility Disorders and Their Clinical Implications in Cirrhosis.

Authors:  Eleni Theocharidou; Ameet Dhar; David Patch
Journal:  Gastroenterol Res Pract       Date:  2017-05-11       Impact factor: 2.260

Review 7.  Intestinal permeability and bacterial translocation in patients with liver disease, focusing on alcoholic aetiology: methods of assessment and therapeutic intervention.

Authors:  Charlotte Skinner; Alex J Thompson; Mark R Thursz; Julian R Marchesi; Nikhil Vergis
Journal:  Therap Adv Gastroenterol       Date:  2020-10-16       Impact factor: 4.409

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.